SCF ADAPTIVE CLINICAL TRIAL DESIGN — THOGALINEX™

Program Code: SCF-CRD-TGX-GBM-0001

Therapeutic Class: Photonic Neuro-Integrative Multi-Omic Modulator

Primary Indication: Glioblastoma (GBM)

Framework: SCF-PCR Braid + Biomarker-Triggered Adaptive System

I. TRIAL DESIGN OBJECTIVE

To operationalize THOGALINEX™ using a biomarker-driven adaptive clinical architecture that:

Dynamically adjusts dose, schedule, and combination intensity
Uses real-time SCF biomarker clusters for decision-making
Maximizes tumor suppression while preserving neural integrity
Achieves FDA-aligned endpoints with enhanced mechanistic validation

II. TRIAL ARCHITECTURE OVERVIEW

Parameter	Design
Trial Type	Phase I/II Adaptive, Biomarker-Guided
Design Model	Bayesian + SCF Adaptive Loop
Population	Recurrent or newly diagnosed GBM
Arms	Dynamic (2–4 arms, adaptive merging/dropping)
Control	Standard of care (SOC: temozolomide ± radiation)
Duration	6–12 months (core), longitudinal extension

III. SCF-PCR THERAPEUTIC BRAID IMPLEMENTATION

Phase	Objective	Biomarker Trigger
Preventative (P)	Stabilize neural & immune baseline	EEG coherence ↑, cytokines ↓
Curative (C)	Tumor cytotoxic + metabolic collapse	ATP ↓, p-mTOR ↓, VEGF ↓
Restorative (R)	Neural repair + photonic integration	BDNF ↑, VEP ↑, ERG ↑

Aligned with SCF Pathophysiology reconstruction logic

IV. PATIENT STRATIFICATION (BIOMARKER-DRIVEN)

Stratification Cohorts

Cohort	Criteria	SCF Rationale
A	High PI3K/mTOR activation	Target-rich tumors
B	High metabolic activity (FDG-PET ↑)	Metabolic vulnerability
C	High neural disruption (EEG entropy ↑)	Neuro-integrative benefit
D	Immunosuppressive phenotype (PD-L1 ↑)	Immune reprogramming

V. DOSING STRATEGY — ADAPTIVE LOGIC ENGINE

Base Regimen

Nanoliposomal THOGALINEX™ (multi-compound)
Weekly or biweekly IV infusion
Optional oral adjunct (metabolic stabilizers)

Adaptive Dosing Algorithm

1. Tumor Collapse Trigger

Biomarker	Threshold	Action
ATP ↓ >40%	Significant metabolic collapse	Maintain dose
Lactate ↓ >30%	Warburg reversal	Maintain
p-mTOR ↓ >50%	Pathway suppression	Maintain

If NOT achieved → escalate dose by 10–20%

2. Neural Safety Trigger

Biomarker	Threshold	Action
Gamma EEG ↓ >15%	Loss of coherence	Reduce dose
BDNF ↓	Neurotoxicity risk	Shift to restorative phase
Cognitive decline	Functional impairment	Pause or reduce

3. Photonic Integration Trigger

Biomarker	Threshold	Action
ERG ↑ >20%	Retinal activation	Continue
VEP latency ↓	Improved signaling	Extend dosing interval
Biophoton emission ↑	System coherence	Transition to maintenance

4. Resistance Detection Trigger

Biomarker	Signal	Action
VEGF rebound ↑	Angiogenic escape	Add anti-angiogenic adjunct
PD-L1 ↑	Immune escape	Add checkpoint inhibitor
miR-21 ↑	Epigenetic resistance	Introduce epigenetic modulator

VI. TREATMENT ARMS (ADAPTIVE)

Arm	Composition	Purpose
Arm 1	THOGALINEX™ monotherapy	Baseline efficacy
Arm 2	THOGALINEX™ + SOC	Comparative standard
Arm 3	THOGALINEX™ + immunotherapy	Immune synergy
Arm 4	THOGALINEX™ + anti-angiogenic	Resistance prevention

Adaptive rule:

Drop arms with inferior biomarker response
Expand high-performing arms

VII. BIOMARKER MONITORING SCHEDULE

Timepoint	Assessments
Baseline	MRI, EEG, PET, genomic
Week 1–2	EEG, metabolomics
Week 4	Proteomics, visual biomarkers
Month 2	MRI, PET
Month 3+	Full panel repeat

VIII. ENDPOINT STRUCTURE

Primary Endpoints

Tumor volume reduction (RANO criteria)
Progression-Free Survival (PFS)
Overall Survival (OS)

Key Secondary Endpoints

Gamma EEG coherence ↑
ATP ↓ / Lactate ↓
VEGF ↓
VEP / ERG improvement

Exploratory Endpoints

Biophoton emission coherence
Connectome restructuring
Neurocognitive recovery

IX. SCF ADAPTIVE DECISION ENGINE (FLOW LOGIC)

Cycle-Based Decision Loop

Administer dose
Measure SCF biomarker clusters
Classify response:

Response Type	Criteria	Action
Full Response	Tumor ↓ + coherence ↑	Maintain
Partial Response	Mixed signals	Adjust dose
Non-Response	No metabolic shift	Escalate
Adverse Signal	Neural decline	De-escalate

Re-enter cycle

X. SAFETY & RISK MANAGEMENT

Risk	Monitoring	Mitigation
Neurotoxicity	EEG, BDNF	Dose modulation
Excess ROS	Redox markers	Antioxidant balancing
Immune overactivation	Cytokines	Immunomodulation
BBB overload	PK monitoring	Delivery adjustment

XI. STATISTICAL FRAMEWORK

Component	Method
Adaptive modeling	Bayesian hierarchical model
Endpoint correlation	Multi-omic regression
Interim analysis	Every 8–12 weeks
Sample size	80–150 (expandable)

XII. REGULATORY STRATEGY

IND submission with biomarker-enriched protocol
Fast Track + Breakthrough Therapy eligibility
Adaptive design aligned with FDA innovation pathways

XIII. TRIAL EXECUTION SUMMARY

Parameter	Status
Precision level	High (real-time adaptation)
Mechanistic validation	Full SCF integration
Risk control	Multi-layered
Regulatory readiness	IND-ready
Innovation level	First-in-class

MASTER REGISTRY INDEX

SCF-CRD-TGX-GBM-0001 — Adaptive Clinical Trial Design
SCF-API-TGX-0001 — THOGALINEX™ API Profile
SCF-BIO-PANEL-PNI-0001 — Biomarker Panel
SCF-SEF-MD-0001 — Synergy Framework
SCF-PATH-EXT-0001 — Pathophysiology Protocol
SCF-FDA-REG-0001 — FDA Drug Approval Processes

Next Strategic Step

Proceed to SCF IND-Enabling Preclinical Program (GLP tox, PK/PD, BBB penetration validation, and in vivo GBM models) to transition this adaptive framework into regulatory submission readiness.